High-dose human ALB (albumin) therapy is highly neuroprotective in animal models of ischaemic stroke. A recently completed 82-subject pilot-phase dose-escalation trial has shown that ALB is safe, with strong preliminary suggestions of possible efficacy. We are now proceeding to a large randomized, double-blinded, placebo-controlled multicentre trial funded by the NIH (National Institutes of Health), the ALIAS (Albumin In Acute Stroke) Phase III Trial, which is designed to ascertain definitively whether high-dose ALB therapy confers neuroprotection in subjects with acute ischaemic stroke treated within 5 h of stroke onset. The primary efficacy outcome measure is a favourable outcome, defined as an NIHSS (NIH Stroke Scale) score of 0-1 or a modified Rankin Scale score of 0-1 at 3 months post-randomization. Separate randomization (1:1) to ALB or placebo therapy will be carried out in two cohorts of 900 subjects each, one that receives standard-of-care thrombolytic therapy and the other that does not. Approx. 60 North American clinical sites will participate. Subject enrolment is expected to commence in July 2006.
Preclinical evidence of ALB (albumin) neuroprotection
Stroke is the third leading cause of death in North America and the chief cause of chronic disability: more than 750 000 individuals continue to suffer an acute stroke each year [1] , and there are as many as 4.8 million chronic stroke survivors [2, 3] . The economic impact of direct costs to our health care system for acute and chronic stroke care is estimated to exceed $50 billion annually, and the overall burden of chronic disability is inestimable.
Multiple pathways and cascades of electrophysiological, biochemical and molecular events interact to cause the death of brain cells, and many potential neuroprotective strategies have been explored (for representative reviews, see [4] [5] [6] [7] [8] [9] ). Importantly, a large number of experimental studies have now conclusively established that, by intervening promptly, it is possible to achieve substantial protection of ischaemically threatened brain tissue.
An ideal neuroprotective agent would be one that: (i) exhibits proven efficacy; (ii) carries minimal risk of adverse effects; (iii) is acceptable both to medical personnel and Key words: albumin, focal cerebral ischaemia, neuroprotection, randomized clinical trial, stroke, thrombolysis. Abbreviations used: ALB, albumin; ALIAS, Albumin In Acute Stroke; CHF, congestive heart failure; CI, confidence interval; CT, computed tomography; MRI, magnetic resonance imaging; mRS, modified Rankin Scale; NIH, National Institutes of Health; NIHSS, NIH Stroke Scale; NINDS, National Institute of Neurological Disorders and Stroke; RR, relative risk; rt-PA, recombinant tissue plasminogen activator; tPA, tissue plasminogen activator. 1 To whom correspondence should be addressed (email mdginsberg@stroke.med.miami. edu).
to patients and their families; and (iv) can be administered without the need for complicated laboratory studies or sophisticated delivery systems. Over the past several years, human ALB has emerged as a highly promising agent of this type. We have shown that moderate-to high-dose human ALB therapy is highly neuroprotective in animal models of both temporary [10] [11] [12] and permanent [13] focal cerebral ischaemia, as well as in global cerebral ischaemia [14] and traumatic brain injury [15] . In ischaemia, ALB (dose, 1.25 g/kg intravenously) diminished total infarct volume by two-thirds and reduced brain oedema by three-quarters or more, with a therapeutic window of efficacy extending to 4 h [12] . In a comprehensive meta-analysis of our focal ischaemia data, ALB-treated rats exhibited approx. 80% reductions in mean cortical infarct volume. We have shown previously that ALB treatment also improves neurobehavioural outcome in a rat model of acute intracerebral haematoma [16] .
ALB acts via multiple mechanisms, which include the amelioration of brain swelling [10] [11] [12] ; the improvement of blood flow to critically perfused brain regions [17] ; the reduction of post-ischaemic thrombosis and blood-element adhesion within the brain's microvasculature [18] ; and the mobilization and supply of important non-esterified fatty acids to the post-ischaemic brain [19] .
Results of pilot clinical trial
The ALIAS (Albumin In Acute Stroke) Pilot Clinical Trial, which was conducted during 2001-2005 at two clinical sites (Universities of Calgary and Miami), was designed to *Adjusted for tPA, ALB × tPA interaction, baseline NIHSS score, age and time from symptom onset to ALB treatment. †Adjusted for tPA. ‡Adjusted for tPA, ALB × tPA interaction, baseline NIHSS score and age.
investigate the safety and tolerability of ALB therapy in acute ischaemic stroke [20, 21] . The Pilot Trial utilized a multipletier, open-label, dose-escalation design in which subjects with acute ischaemic stroke [NIHSS of 6 or above; where NIHSS is NIH (National Institutes of Health) Stroke Scale] received a 2 h infusion of 25% human ALB, commencing within 16 h of stroke onset. Six successive ALB dose-tiers were assessed, ranging from 0.37 to 2.05 g/kg. Neurological and cardiac functions were sequentially monitored. At 3 months, the NIHSS, mRS (modified Rankin Scale) and Barthel Index were measured. ALB therapy was well tolerated without major doselimiting complications. A total of 82 subjects (mean age, 65 years) received ALB at 7.8 ± 3.4 h after stroke onset (mean ± S.D.). Forty-two patients also received standard-ofcare intravenous tPA (tissue plasminogen activator). Vital signs were unaltered by ALB treatment. Dose-related increases in plasma ALB and mild haemodilution were maximal at 4-12 h. Plasma BNP (brain natriuretic peptide) levels increased at 24 h post-ALB; this was strongly correlated with patient age, but not with stroke severity, and did not predict cardiac adverse events. The sole ALB-related adverse event was mild or moderate pulmonary oedema in 13.4% of subjects, which was readily managed with diuretics. In the tPAtreated subgroup, symptomatic intracranial haemorrhage occurred in only 1 of 42 subjects. tPA therapy did not affect the safety profile of ALB [20] .
In order to analyse the pilot-trial data for preliminary evidence of treatment efficacy at 3 months, we compared the highest three, putatively therapeutic ALB dose-tiers (1.37-2.05 g/kg) with the lowest three, presumed subtherapeutic doses (0.34-1.03 g/kg) and with historical cohort data derived from the NINDS (National Institute of Neurological Disorders and Stroke) rt-PA (recombinant tissue plasminogen activator) Stroke Study [22] . After adjusting for the tPA effect, the probability of good outcome (defined as mRS 0-1 or NIHSS 0-1 at 3 months) at the highest three ALB doses was 81% greater than that in the lower dose-tiers [RR (relative risk): 1.81; 95% CI (confidence interval): 1.11, 2.94] (Table 1A) , and was 95% greater than that in the comparable NINDS rt-PA Stroke Study cohort (RR: 1.95; 95% CI: 1.47, 2.57) (Table 1B) [21] . The tPA-treated subjects who received higher-dose ALB were 3 times more likely to achieve a good outcome than subjects receiving lower-dose ALB, suggesting a positive synergistic effect between ALB and tPA [21] .
These results, confirming that high-dose ALB therapy is safe and suggesting that it may be neuroprotective after ischaemic stroke, led us to design a multicentre, randomized, placebo-controlled efficacy trial of ALB in acute ischaemic stroke: the ALIAS Phase III Trial.
Design of the ALIAS Phase III multicentre trial
The ALIAS Phase III Trial is a large randomized, doubleblinded, placebo-controlled multicentre efficacy trial funded by the NINDS, NIH. The Trial is designed to ascertain Episode/exacerbation of CHF from any cause in the last 6 months. (An episode of CHF is any heart failure that required a change in medication, diet or hospitalization.) Known valvular heart disease with CHF in the last 6 months.
Known (or in the Investigator's judgement) existence of severe aortic stenosis or mitral stenosis. Cardiac surgery involving thoracotomy (e.g. coronary artery bypass graft and valve replacement surgery) in the last 6 months. Acute myocardial infarction in the last 3 months.
Signs or symptoms of acute myocardial infarction, including ECG (electrocardiogram) findings, on admission. Suspicion of aortic dissection on admission. Acute arrhythmia (including any tachy-or brady-cardia) with haemodynamic instability on admission (systolic blood pressure <100 mmHg).
Findings on physical examination of any of the following: (i) jugular venous distension (>4 cm above the sternal angle); (ii) third heart sound; (iii) resting tachycardia (heart rate >100 min −1 ) attributable to CHF; (iv) abnormal hepatojugular reflux; (v) lower extremity pitting oedema attributable to CHF or without apparent cause; (vi) bilateral rales; and/or (vii) if a chest X-ray is performed, definite evidence of pulmonary oedema, bilateral pleural effusion or pulmonary vascular redistribution. Current acute or chronic lung disease requiring supplemental chronic or intermittent oxygen therapy. Historical mRS 2.
Profound dehydration. Fever, defined as core body temperature >37.5 • C (99.5 • F). Serum creatinine >2.0 mg/dl or 180 µmol/l.
Severe chronic anaemia (haemoglobin <7.5 g/dl or 75g/l). Evidence of intracranial haemorrhage (intracerebral haematoma, intraventricular haemorrhage, subarachnoid haemorrhage, epidural haemorrhage and acute or chronic subdural haematoma) on the baseline CT or MRI scan. History of or known allergy to albumin. History of or known allergy to natural rubber latex.
Pregnancy, breastfeeding or positive pregnancy test. Concurrent participation in any other therapeutic clinical trial. Evidence of any other major life-threatening or serious medical condition that would prevent completion of the study protocol, impair the assessment of outcome, or in which ALB therapy would be contraindicated or might cause harm to the subject.
whether high-dose ALB therapy confers neuroprotection in acute ischaemic stroke over and above the best standard of care. The Study Chair (Principal Investigator) is Dr Ginsberg at the University of Miami. The Data and Project Management and Statistics Center (Dr Palesch, Director) is at the Medical University of South Carolina (Charleston, SC, U.S.A.). The Canadian Coordinating Center (Dr Hill, Director) is at the University of Calgary (Calgary, AB, Canada). Approximately 60 clinical sites in the United States, Canada, and possibly other countries, will participate in the Trial.
The ALIAS Trial will consist of two separate but concurrently implemented two-arm, randomized, double-blinded, placebo-controlled trials of ALB therapy in acute ischaemic stroke patients. Thus separate randomization to ALB or placebo will be carried out in two cohorts of approx. 900 subjects each: (i) a cohort that receives standard-of-care thrombolytic treatment with intravenous and/or intraarterial tPA; and (ii) a cohort that does not receive tPA therapy. Determination of tPA therapy is based on clinical judgment. Within each cohort, randomization will be stratified by clinical centre, and subjects will be randomized in a 1:1 ratio to intravenous treatment with either ALB or placebo (saline) solution.
The inclusion criteria are straightforward: (i) diagnosis of acute ischaemic stroke [intracranial haemorrhage excluded by CT (computed tomography) or MRI (magnetic resonance imaging)]; (ii) age 18 years or above; (iii) NIHSS score of 6 or greater as assessed immediately prior to tPA treatment if the patient is eligible for tPA, or immediately prior to randomization for patients not eligible for tPA; (iv) initiation of ALB/placebo therapy within 5 h of stroke onset; and (v) obtaining of informed consent. The exclusion criteria, listed in Table 2 , are chiefly intended to exclude subjects with recent CHF (congestive heart failure) or cardiopulmonary pathology.
Upon randomization, each subject will receive an intravenous infusion of either 25% ALB solution, or isoosmotic saline solution, over the course of 2 h. The total ALB dose (2.0 g/kg or 8.0 ml/kg of 25% human serum ALB) is based on the subject's estimated weight at the time of randomization and must not exceed 750 ml. The study drug infusion must start within 60 min of the start of the tPA infusion for the tPA cohort and within 60 min of randomization for the non-tPA cohort. Blinding of study drugs for the ALIAS Trial requires that the containers for ALB and saline placebo be identical and indistinguishable and that the product identity must not be revealed while flowing through the administration set. Thus the study-drug bottles are encased in masking cartons, and green-tinted intravenous administration sets are used to disguise the agent.
Each subject is monitored closely throughout his/her hospitalization for the qualifying stroke and is followed for 1 year from randomization. The primary efficacy outcome is a favourable outcome compared with placebo therapy as assessed at a clinic visit 3 months following randomization. Favourable outcome is defined as either an NIHSS score of 0 or 1, or an mRS of 0 or 1, or both, at 3 months. In addition, each subject will be contacted by telephone at 1, 6, 9 and 12 months from randomization. A variety of secondary outcome measures will be assessed, including functional outcome on the Barthel Index; quality-of-life by EuroQol and SSQOL (Stroke-Specific Quality of Life) instruments; recurrent stroke as assessed by the QVSFS (Questionnaire to Validate Stroke-Free Status); cognition as measured by Trailmaking A and B; and mortality.
Monitoring and oversight
Two experienced critical-care neurologists serve as external Medical Safety Monitors; they are responsible for reviewing all serious adverse events in a blinded fashion, adjudicating their unexpectedness and their relatedness to the study drug; and assessing adverse outcome events (e.g. recurrent stroke, myocardial infarction and symptomatic intracranial haemorrhage). A DSMB (Data Safety and Monitoring Board) appointed and managed by NINDS is responsible for overseeing the safety of Trial participants by performing periodic data reviews.
Progress of the ALIAS Phase III Trial
To date, approx. 50 clinical sites in the United States and Canada have agreed to participate in the Trial. Enrolment of the first subjects is expected in July 2006.
